Table 3.
Procedural data and device characteristics
| Variable | All | De novo | BMS-ISR | DES-ISR | p value |
|---|---|---|---|---|---|
| Number of lesions | 496 | 386 | 19 | 91 | – |
| DCBs used | 528 | 410 | 21 | 97 | – |
| Predilatation with scoring balloon | 496 (100%) | 386 (100%) | 19 (100%) | 91 (100%) | – |
| Scoring balloon diameter (mm)a | 2.53 ± 0.45 | 2.43 ± 0.41 | 2.71 ± 0.31 | 2.92 ± 0.42 | < 0.001 |
| Predilatation scoring balloon pressure (atm)a | 11.6 ± 3.3 | 11.0 ± 3.0 | 15.4 ± 3.9 | 13.4 ± 3.1 | < 0.001 |
| DCB diameter (mm)a | 2.71 ± 0.45 | 2.60 ± 0.39 | 3.00 ± 0.35 | 3.10 ± 0.43 | < 0.001 |
| DCB length (mm)a | 24.1 ± 7.1 | 24.4 ± 7.0 | 22.7 ± 7.0 | 22.7 ± 7.0 | 0.070 |
| DCB inflation pressure (atm)a | 9.4 ± 3.2 | 8.7 ± 2.6 | 12.9 ± 4.3 | 11.5 ± 3.9 | < 0.001 |
| Bailout stenting in target lesion | 1.2% (6/496) | 1.3% (5/386) | 5.3% (1/19) | 0.0% (0/91) | 0.153 |
| Additional DES in non-target lesions | 9 (1.9%) | 6 (1.6%) | 1 (5.3%) | 2 (2.4%) | 0.482 |
| Overall technical success per patient | 480 (99.8%) | 376 (99.7%) | 19 (100.0%) | 85 (100.0%) | 0.871 |
| Multi-vessel PCI | 184 (38.3%) | 165 (43.8%) | 8 (42.1%) | 11 (12.9%) | < 0.001 |
| Additional non-target lesions treated | 0.6 ± 0.9 | 0.8 ± 1.0 | 0.7 ± 0.2 | 0.5 ± 0.1 | < 0.001 |
| Type of DES-ISR | – | ||||
| PES-ISR | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | 1 (1.1%) | |
| SES-ISR | 9 (8.2%) | 0 (0.0%) | 0 (0.0%) | 9 (9.9%) | |
| ZES-ISR | 14 (12.7%) | 0 (0.0%) | 0 (0.0%) | 14 (15.4%) | |
| BES-ISR | 4 (3.6%) | 0 (0.0%) | 0 (0.0%) | 4 (4.4%) | |
| EES-ISR | 37 (33.6%) | 0 (0.0%) | 0 (0.0%) | 37 (40.7%) | |
| Biomatrix-ISR | 11 (10.0%) | 0 (0.0%) | 0 (0.0%) | 11 (12.1%) | |
| PF-SES-ISR | 5 (4.5%) | 0 (0.0%) | 0 (0.0%) | 5 (5.5%) | |
| Absorb-ISR | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | 1 (1.1%) | |
| Other DES-ISR | 7 (6.4%) | 0 (0.0%) | 0 (0.0%) | 7 (7.7%) | |
| Type of BMS-ISR | |||||
| CoCr-ISR | 6 (5.5%) | 0 (0.0%) | 6 (31.1%) | 0 (0.0%) | |
| CrCo-ISR | 4 (3.6%) | 0 (0.0%) | 4 (21.1%) | 0 (0.0%) | |
| Stainless steel ISR | 4 (3.6%) | 0 (0.0%) | 2 (10.5%) | 2 (2.2%) | |
| Other BMS-ISR | 7 (6.4%) | 0 (0.0%) | 7 (36.8%) | 0 (0.0%) | |
| Time since stenting, monthsa | 45.5 ± 53.5 | – | 127.1 ± 60.3 | 26.7 ± 28.4 | < 0.001 |
BMS bare metal stents, DCB drug-coated balloon, DES drug-eluting stent, EES everolimus-eluting stents, ISR in-stent restenosis, PCI percutaneous coronary intervention, PES paclitaxel-eluting stent, PF polymer-free, SES sirolimus-eluting stent, ZES zotarolimus-eluting stent
aSingle-factor ANOVA, otherwise χ2 or Fisher’s exact test whenever applicable